Blackstone (BX) Executes Triple Play: Data Centers, Automotive Assets, and Cancer Research

TLDR

• Blackstone plans to debut a publicly accessible investment vehicle dedicated to acquiring AI-focused data center infrastructure with multi-billion dollar ambitions
• Initial capital raising efforts target sovereign wealth funds and major institutional investment partners
• Both Blackstone and Brookfield submitted competing proposals valued at minimum €8 billion to acquire Volkswagen’s heavy-duty engine division, Everllence SE
• A collaborative funding arrangement between Blackstone Life Sciences and Johnson & Johnson will support development of bleximenib, an experimental AML treatment
• RBC Capital launched research coverage on February 23 with Outperform designation and $179 share price objective

The private equity heavyweight is preparing to introduce a fresh publicly traded acquisition platform dedicated exclusively to AI data center assets. The initiative aims to democratize access to AI infrastructure investments — a sector where Blackstone seeks commanding market position.

Blackstone Inc., BX

The initial phase focuses on securing commitments from sovereign wealth entities and major institutional capital providers. Following this foundation, the firm intends to attract investment capital measuring in the tens of billions from a wider investor universe.

The strategy demonstrates significant ambition. However, skepticism exists regarding market timing.

Certain market participants have questioned whether massive AI training complexes constructed in remote locations might face obsolescence risks as technological capabilities advance. Blackstone appears prepared to address these reservations directly.

This initiative represents a component of the firm’s larger objective to expand beyond its established pension fund and endowment client relationships. Individual investors now represent an increasingly important strategic focus.

Volkswagen Unit Bid

Regarding transaction activity, Blackstone and Brookfield Asset Management (NYSE: BAM) have each presented acquisition proposals exceeding €8 billion ($9.4 billion) to secure controlling ownership in Volkswagen’s Everllence SE division.

Everllence specializes in manufacturing marine propulsion systems and industrial power generation turbines. Volkswagen has pursued divestiture of this operation as component of broader corporate restructuring and margin enhancement initiatives.

Additional competing bidders include Advent International, Bain Capital, EQT AB, and CVC Capital Partners — all successfully advancing to subsequent bidding stages.

Transaction completion remains uncertain. Bloomberg sources indicated negotiations continue without final determination.

Biotech and Analyst Coverage

On February 23, Blackstone Life Sciences revealed a collaborative financing agreement with Johnson & Johnson supporting clinical progression of bleximenib, an experimental oral medication designed to treat acute myeloid leukemia.

AML represents the most prevalent acute leukemia diagnosis among adult patients and demonstrates the poorest survival outcomes across all leukemia classifications. Company leadership characterized this condition as presenting exceptional therapeutic challenges.

This marks the inaugural co-funding partnership between BXLS and Johnson & Johnson, representing a significant milestone for Blackstone’s healthcare investment division.

Simultaneously, RBC Capital established research coverage of Blackstone with an Outperform recommendation and $179 price objective.

Blackstone conducts operations through four primary business segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions.

BX stock declined 3.88% on February 27, coinciding with public disclosure of the AI data center platform and Volkswagen competitive bid developments.

The post Blackstone (BX) Executes Triple Play: Data Centers, Automotive Assets, and Cancer Research appeared first on Blockonomi.